T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions
Cancers · 18.05.2023 · 15 (10) · 2824
DOI: 10.3390/cancers15102824 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.05.2023. Verfasst von Mohamed Shanshal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mayo Clinic, Rochester, MN 55902, USA. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Monoclonal antibody treatment initially heralded an era of molecularly targeted therapy in oncology and is now widely applied in modulating anti-cancer immunity by targeting programmed cell receptors (PD-1, PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and, more recently, lymphocyte-activation gene 3 (LAG3). Chimeric antigen receptor T-cell therapy (CAR-T) recently proved to be a valid approach to inducing anti-cancer immunity by directly modifying the host’s immune cells. However, such cell-based therapy requires extensive resources such as leukapheresis, ex vivo modification and expansion of cytotoxic T-cells and current Good Manufacturing Practice (cGMP) laboratories and presents significant logistical challenges. Bi-/trispecific antibody technology is a novel pharmaceutical approach to facilitate the engagement of effector immune cells to potentially multiple cancer epitopes, e.g., the recently approved blinatumomab. This opens the opportunity to develop ‘off-the-shelf’ anti-cancer agents that achieve similar and/or complementary anti-cancer effects as those of modified immune cell therapy. The majority of bi-/trispecific antibodies target the tumor-associated antigens (TAA) located on the extracellular surface of cancer cells. The extracellular antigens represent just a small percentage of known TAAs and are often associated with higher toxicities because some of them are expressed on normal cells (off-target toxicity). In contrast, the targeting of intracellular TAAs such as mutant RAS and TP53 may lead to fewer off-target toxicities while still achieving the desired antitumor efficacy (on-target toxicity). Here, we provide a comprehensive review on the emerging field of bi-/tri-specific T-cell engagers and potential therapeutic opportunities.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Mayo Clinic, Rochester, MN 55902, USA.
- Cleveland Clinic, Cleveland, OH 44195, USA.
ORCID-Profile: Wen Wee Ma
Zitieren
APA
Shanshal, M., Caimi, P. F., Adjei, A. A., & Ma, W. W. (2023). T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions. Cancers, 15(10), 2824. https://doi.org/10.3390/cancers15102824
Vancouver
Shanshal M, Caimi PF, Adjei AA, Ma WW. T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions. Cancers. 2023;15(10):2824. doi:10.3390/cancers15102824
BibTeX
@article{Shanshal2023,
author = {Shanshal, Mohamed and Caimi, Paolo F and Adjei, Alex A and Ma, Wen Wee},
title = {T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions},
journal = {Cancers},
year = {2023},
volume = {15},
number = {10},
pages = {2824},
doi = {10.3390/cancers15102824}
}
EUVIMED